Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11)

Journal of Gene Medicine

Volumn 9, Issue 4, 2007, Pages 244-252

  Matzow, Torkjel ^a,c   Cowen, Rachel L ^b   Williams, Kaye J ^b   Telfer, Brian A ^b   Flint, Pamela J ^a   Southgate, Thomas D ^a   Saunders, Mark P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Carboxylesterase; CPT 11; Gene therapy; Hypoxia; Irinotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOVIRUS VECTOR; CARBOXYLESTERASE; COMPLEMENTARY DNA; IRINOTECAN; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOMA CELL; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FIBROSARCOMA; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIMIAN VIRUS 40; TREATMENT DURATION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; CELL HYPOXIA; CELL LINE; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; NEOPLASMS; RABBITS; TRANSPLANTATION, HETEROLOGOUS;

ORYCTOLAGUS CUNICULUS;

EID: 34248548838     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1016     Document Type: Article

References (43)

1. Hockel M, Schlenger K, Knoop C, et al. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991; 51: 6098-6102.
2. Vaupel P, Schlenger K, Knoop C, et al. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991; 51: 3316-3322.
3. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-4515.
4. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
5. Brizel DM, Dodge RK, Clough RW, et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53: 113-117.
6. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64: 993-998.
7. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.
8. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447-5454.
9. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Develop 2001; 11: 293-299.
10. Saunders MP, Patterson AV, Stratford IJ. Radiation sensitisation: hypoxia-selective therapeutics. In Oxford Textbook of Oncology (2nd edn). Oxford University Press: Oxford, 2002.
11. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
12. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
13. Satoh T, Hosokawa M, Atsumi R, et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 1994; 17: 662-664.
14. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-4191.
15. Rivory LP, Haaz MC, Canal P, et al. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997; 3: 1261-1266.
16. Guichard S, Tenet C, Hennebelle I, et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999; 80: 364-370.
17. Kojima A, Hackett NR, Ohwada A, et al. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 1998; 101: 1789-1796.
18. Potter PM, Pawlik CA, Morton CL, et al. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998; 58: 2646-2651.
19. Cowen RL, Williams KJ, Chinje EC, et al. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res 2004; 64: 1396-1402.
20. Carmichael J, DeGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
21. Workman P, Balmain A, Hickman JA, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 1988; 22: 195-201.
22. Patterson AV, Williams KJ, Cowen RL, et al. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 2002; 9: 946-954.
23. Morton CL, Wierdl M, Oliver L, et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res 2000; 60: 4206-4210.
24. Wadkins RM, Hyatt JL, Yoon KJ, et al. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhoea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 2004; 65: 1336-1343.
25. Oosterhoff D, Overmeer RM, de Graaf M, et al. Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. Br J Cancer 2005; 92: 882-887.
26. Meck MM, Wierdl M, Wagner LM, et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 2001; 61: 5083-5089.
27. Kojima A, Hackett NR, Crystal RG. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Cancer Res 1998; 58: 4368-4374.
28. Firth JD, Ebert BL, Pugh CW, et al. Oxygen-regulated control elements in the phosphoglycerate kinase-1 and lactate-dehydrogenase-a genes - similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci U S A 1994; 91: 6496-6500.
29. Boast K, Binley K, Igball S, et al. Characterization of physiologically regulated vectors for the treatment of ischemic disease. Hum Gene Ther 1999; 10: 2197-2208.
30. Binley K, Askham Z, Martin L, et al. Hypoxia-mediated tumour targeting. Gene Ther 2003; 10: 540-549.
31. Danks MK, Morton CL, Krull FJ, et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999; 5: 917-924.
32. Humerickhouse R, Lohrbach K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60: 1189-1192.
33. Khanna R, Morton CL, Danks MK, et al. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 2000; 60: 4725-4728.
34. Yoon KJ, Hyatt JL, Morton CL, et al. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. Mol Cancer Ther 2004; 3: 903-909.
35. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-520.
36. Fleischmann E, Herbst F, Kugener A, et al. Mild hypercapnia increases subcutaneous and colonic oxygen tension in patients given 80% inspired oxygen during abdominal surgery. Anesthesiology 2006; 104: 944-949.
37. Sheridan WG, Lowndes RH, Young HL. Intraoperative tissue oximetry in the human gastrointestinal tract. Am J Surg. 1990; 159: 314-319.
38. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276.
39. Snyder JR, Pascoe JR, Holland M, et al. Surface oximetry of healthy and ischemic equine intestine. Am J Vet Res. 1986; 47: 2530-2535.
40. Leith JT, Padfield G, Quaranto L, et al. Effect of preirradiation of transplantation site on growth characteristics and hypoxic fractions in human colon tumor xenografts. Cancer Res 1992; 52: 2162-2166.
41. Oosterhoff D, Witlox MA, van Beusechem VW, et al. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol Cancer Ther 2003; 2: 765-771.
42. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62: 4316-4324.
43. Koch S, Mayer F, Honecker F, et al. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 2003; 89: 2132-2139.